期刊
EUROPEAN JOURNAL OF NEUROLOGY
卷 25, 期 6, 页码 811-817出版社
WILEY
DOI: 10.1111/ene.13621
关键词
flunarizine; migraine; migraine prevention; headache; prophylaxis
资金
- Allergan
- Amgen
- Eli-Lilly and Company
- eNeura
- Ajinomoto Pharmaceuticals Co.
- Akita Biomedical
- Alder Bio-pharmaceuticals
- Autonomic Technologies Inc.
- Avanir Pharma
- Cipla Ltd
- Colucid Pharmaceuticals Ltd
- Dr Reddy's Laboratories
- Electrocore LLC
- Ethicon, United States
- W.L. Gore Associates
- Heptares Therapeutics
- Novartis
- Nupathe Inc.
- Pfizer Inc.
- Promius Pharma
- Scion
- Teva Pharmaceuticals
- Trigemina Inc.
- MedicoLegal work
- Journal Watch
- Up-to-Date
- Oxford University Press
Background and purposeFor over 20 years, as a group we have been using flunarizine in primary headache disorders. Flunarizine is widely used in Europe, but not licensed in the UK. In September 2014, the National Institute for Clinical Excellence published supportive guidelines for flunarizine use in migraine, based on randomized controlled evidence that it is as effective as propranolol and topiramate in adults. MethodsWe reviewed a cohort of adult patients (n = 200) treated with flunarizine from our practice. The clinical information of these patients, i.e. diagnosis, dose, efficacy, side effects and duration of treatment, was collected. ResultsThe most common indication for flunarizine use was chronic migraine, followed by migraine with aura, sporadic hemiplegic migraine, familial hemiplegic migraine and new daily persistent headache with migrainous features. Flunarizine was generally effective, with only 24% (n = 47) of patients reporting no clinical effect. The most common dose used was 10 mg per day. Duration of treatment information was available for 39% (n = 78) of patients. Of these patients, 64% (n = 50) continued treatment for more than 1 year. Doses up to 15 mg were generally well tolerated, with only 10.5% (n = 21) of patients stopping treatment due to adverse effects. The most common adverse events were tiredness, mood change and weight gain. ConclusionThe data provide supportive evidence from tertiary headache practice in the UK for the use of flunarizine in migraine. The data encourages development of future guidance regarding flunarizine use in headache centres in countries where its use is not routine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据